XML 78 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingent Liabilities (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 29, 2024
Other Commitments [Line Items]        
Decsription of occurrence for payments upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than  $3,000 thousand.      
Maximum percentage of payments of royalties (as a percent) 100.00%      
Cumulative Amounts Of Grants Received And Recognized $ 1,227      
Royality expenses 418 $ 4,832 $ 5,222  
Bank restricted deposit $ 76      
Accrued Income Taxes       $ 538
Accretion Expense     $ 638  
New Drug Application and Biological License Application [Member]        
Other Commitments [Line Items]        
Description of application payment for licensed product $100 thousands upon submission of a New Drug Application (“NDA”), Biological License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug Administration (“FDA”), $100 thousands upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousands dollars upon submission of a similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.      
Royalty payments on sale of product (as a percent) 3.00%      
Capital Additions One [Member]        
Other Commitments [Line Items]        
Description of application payment for licensed product $200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousands per Licensed Product, provided that for each jurisdiction, payment shall be made only once.